Keenova reports Q1 net sales $468M, loss $114M; reaffirms FY guidance

Keenova Therapeutics plc

2026-Q1 EPS reported -$2.87 revenue$468,300,000

Acthar Gel net sales $170M (+47% YoY); XIAFLEX net sales $134M.
Loss from continuing ops $114M; adjusted EBITDA $174M.
Reaffirmed FY2026 guidance: net sales $1.94B-$2.00B, adj. EBITDA $730M-$760M.
Realized $23M in merger synergies in Q1; on track for $100M in 2026.
Pipeline: Phase 3 plantar fibromatosis topline expected July 2026; FDA EOP2 meeting for hammer toe June 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

Keenova Therapeutics plc reported the first quarter ended March 31, 2026 results: revenue $468 million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2026
Revenue: $468 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Today at 8:00 a.m. ET First Quarter 2026 Highlights 3 • Acthar Gel net sales of $170 million • XIAFLEX net sales of $134 million • Net sales from continuing operations of $468 million • Loss from continuing operations of $114 million • Adjusted EBITDA from continuing operations of $174 million DUBLIN, May 12, 2026 – Keenova Therapeutics plc (“Keenova” or the

View on SEC.gov

572 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001628280-26-033847

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.